Basilea News Basilea News en Wed, 25 Nov 2015 13:13:22 +0100 Wed, 25 Nov 2015 13:13:22 +0100 Chameleon CMS (Webmaster Webmaster) (Webmaster Webmaster) <![CDATA[Basilea to present preclinical brain tumor stem cell data on its oncology drug candidate BAL101553]]>
  • Tumor check point controller BAL101553 demonstrates inhibitory activity on tumor stem cell self-renewal and invasion in models of brain cancer
  • Loss of glioblastoma stem cell properties induced by BAL101553 correlates with EB1 expression levels in vitro and in animal models
  • ]]>
    Thu, 05 Nov 2015 07:15:00 +0100
    <![CDATA[Basilea announces that European Commission maintained isavuconazole's orphan drug status]]> Fri, 23 Oct 2015 07:15:00 +0200 <![CDATA[Basilea announces filing of registration statement for a proposed offering in the United States]]>
  • Basilea seeks access to U.S. public equity market
  • The offering is intended to:
    • increase liquidity, visibility and coverage for Basilea shares
    • facilitate Basilea's participation in ceftobiprole phase 3 development program to gain U.S. regulatory approval
    • support commercialization activities of ceftobiprole and
      isavuconazole, and
    • further advance Basilea's research and development projects
    ]]> Fri, 16 Oct 2015 20:43:23 +0200 <![CDATA[Basilea announces that European Commission approves isavuconazole (CRESEMBA®) as a treatment for invasive aspergillosis and mucormycosis in the European Union]]>
  • Basilea's second anti-infective product approved in Europe, providing potential commercial synergy with Zevtera® (ceftobiprole)
  • ]]>
    Fri, 16 Oct 2015 16:48:05 +0200
    <![CDATA[Basilea signs exclusive distribution agreement for Zevtera® (ceftobiprole medocaril) in the Middle East and North Africa with Hikma Pharmaceuticals LLC]]>
  • Hikma to commercialize antibiotic Zevtera® in the Middle East and North Africa (MENA) region
  • Agreement expands the global availability of Zevtera®
  • ]]>
    Thu, 15 Oct 2015 07:15:00 +0200
    <![CDATA[Basilea announces that Health Canada approved ZEVTERA® for the treatment of bacterial lung infections]]> Mon, 12 Oct 2015 07:15:00 +0200 <![CDATA[Basilea announces development of inhaled dosage form of its Gram-negative antibiotic BAL30072 as part of European iABC program]]>
  • Start of "inhaled Antibiotics in Bronchiectasis and Cystic fibrosis" (iABC) program to develop new antibiotic treatments for cystic fibrosis and bronchiectasis
  • ]]>
    Mon, 07 Sep 2015 07:15:00 +0200
    <![CDATA[Basilea's Chief Technology Officer Dr. Ingrid Heinze-Krauss to retire and Dr. Günter Ditzinger named as successor]]> Fri, 28 Aug 2015 07:15:00 +0200 <![CDATA[Basilea reports 2015 half-year results - Major milestones achieved for CRESEMBA® and Zevtera®]]>
  • Antifungal CRESEMBA® (isavuconazole) received U.S. approval and is recommended for approval in the European Union
  • Antibiotic Zevtera®/Mabelio® (ceftobiprole medocaril) launched in four European countries
  • Ceftobiprole designated as a Qualified Infectious Disease Product for the treatment of lung and skin infections by U.S. FDA
  • Additional oncology program (panRAF kinase inhibitor BAL3833) entered phase 1 of clinical development
  • Cash and short-term investments of CHF 218.4 million
  • ]]>
    Fri, 14 Aug 2015 07:15:00 +0200
    <![CDATA[Basilea reports that ceftobiprole received QIDP designation from U.S. FDA for the treatment of lung and skin infections]]> Wed, 12 Aug 2015 07:15:00 +0200